Illumina Opens First Commercial and Customer Training Center in France
Illumina, Inc. (NASDAQ:ILMN) today announced the opening of its Solutions Center on the Genopole Campus in Évry, near Paris.
The leading-edge customer training center will offer demonstrations, instruction, and education in the latest genomics technologies from Illumina for up to 1,000 scientists a year, providing direct links to Illumina’s global network of facilities and in-house experts. The center will also accommodate Illumina’s first commercial office on the European continent to provide support in the development of skills for the expanding genomics industry in France.
"Illumina's unmatched success and reputation as a global leader in genomics is the perfect fit for the Genopole campus, which brings together the key elements needed for our business to thrive, and we look forward to extending our relationships in France," said Paula Dowdy, Senior Vice President and General Manager, Illumina, Europe, Middle East, and Africa. "The French government’s commitment to its own Genome Project demonstrates the value it places on genomics as part of the strategy to provide better future healthcare."
Genopole, France’s leading biocluster for biotechnologies and research in genomics and genetics, is built upon the model of American and European campuses and unites innovative high-tech life sciences companies, public and private research and higher education facilities at a single site in Évry, near Paris.
“We are very proud that Illumina has chosen Genopole to establish its Solutions Center in France,” said Jean-Marc Grognet, CEO of Genopole. “France Médecine Génomique 2025 - the national personalized medicine initiative - has also selected Genopole for its Reference, Expertise, Innovation and Transfer Center (CREFIX), thus building on the strength of the National Research Center on Human Genomics already established on our site by the French Alternative Energies and Atomic Energy Commission (CEA). The arrival of Illumina demonstrates the central role that Genopole plays in the development of personalized medicine and we are happy that its Solutions Center will attract more users to our site.”
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Genopole is France’s leading biocluster dedicated to biotechnology and research in genomics and genetics, with 86 biotechnology companies, 19 research laboratories, 25 technology platforms as well as university courses (university Évry-Paris Saclay). Its objective is to create and support biotechnology companies and technology transfer towards industry, help the development of life science research and develop top level courses in this field. Genopole is mainly supported by the French government, the Ile-de-France region, the Essonne department, the agglomeìration Grand Paris Sud, the city of Évry and the AFM-Telethon. www.genopole.fr
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Jacquie Ross, CFA
Investors: +1 858-882-2172
David Robertson, MCIPR
Media: Europe, Middle East, and Africa +44 (0)1223 824909
Media: US +1 858-882-6822
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FINEOS Momentum Continues with New Office Opening and New Jobs Driven by Product Expansion17.1.2018 10:28 | Pressemelding
FINEOS Corporation, the market leading provider of core processing systems for Life, Accident and Health insurance, today announced continued growth and momentum, including a new North American office in Atlanta, Georgia, and an increase in the workforce by 50 staff in six months. This growth has been driven by new customers in Claims, Absence and Paid Family Leave and the preference carriers have for FINEOS products in the Cloud. Speaking about the announcement, Michael Kelly, CEO, FINEOS said, “We are growing strongly, winning new business and investing heavily in FINEOS Absence and Paid Family Leave as part of FINEOS AdminSuite, our next generation core product suite for Life, Accident and Health insurance. By recruiting new talent, with the right level of business and technical expertise, we will continue to increase our market share, enter new markets and grow our overall business”. FINEOS continues to recruit for our Java Engineering practice in Dublin and Gdansk (Software Engine
1000 Girls in Pakistan to Receive Education through The Big Heart Foundation and Malala Fund17.1.2018 09:48 | Pressemelding
The Big Heart Foundation (TBHF), a global humanitarian charity based in Sharjah, UAE, is funding the second phase of a school for girls in Pakistan in keeping with its dedication to ensuring children have access to education, enabling them to contribute to the development of their communities. The project will be funded by the TBHF ‘Girl Child Fund’, in cooperation with the ‘Malala Fund’, launched by Nobel Laureate and education activist, Malala Yousafzai. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117005590/en/ Sheikh Sultan bin Ahmed Al Qasimi and Malala Yousafzai witnessing the signing between TBHF and Malala Fund - Source: The Big Heart Foundation The initiative was announced in the presence of Sheikh Sultan bin Ahmed Al Qasimi, The Big Heart Foundation’s Humanitarian Envoy, and Malala Yousafzai following an agreement signed in Oxford by Mariam Al Hammadi, Director of TBHF, and Farah Mohamed, CEO of the Malala Fund
Call for IBC2018 Technical Papers Submission is Now Open!17.1.2018 09:17 | Pressemelding
IBC is delighted to announce that it is now accepting synopsis submissions for its prestigious Technical Papers for the IBC2018 Conference. For over 50 years, IBC has been the world's foremost forum for the unveiling, explanation, exploration and dissemination of the very latest concepts in media technology. Its published proceedings are a collected history of broadcasting and media technology written by engineers and scientists who have personally shaped today's exciting and diverse industry. The selected 2018 Technical Papers will not form part of a single conference stream, as in previous years. Instead, they will be integrated with business and strategic presentations within specific themes throughout the conference. This will bring ground-breaking technologies closer to the attention of more delegates, and will ensure these delegates have the opportunity to hear first-hand presentations from the world's brightest innovators and researchers. IBC looks forward to receiving proposals
Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer17.1.2018 08:00 | Pressemelding
Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has expanded its CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer. The exquisite sensitivity and precision of the assays support clinicians in the rapidly evolving European clinical practice of therapy cessation for long-term responders on tyrosine kinase inhibitor (TKI) therapies. The available platforms, which also include the Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument, improve the reach of the portfolio in Europe and Latin America. “As a global solutions provider, we are committed to ensuring that our best-in-class CML monitoring assays are widely available to deliver powerful answers that can impact patient decisions,” said Matthew McManus, M.D., Ph.
Login VSI Announces Free Meltdown/Spectre Emergency Edition17.1.2018 08:00 | Pressemelding
Today software solution provider Login VSI (www.loginvsi.com), the industry leader in VDI and DaaS performance testing, announces the temporary availability of a free, full-production, license of their flagship product Login VSI to every organization using Citrix XenApp, Citrix XenDesktop, VMware Horizon, or Microsoft Remote Desktop Services (RDS). This Emergency Edition will be free for all end-user organizations looking to test the performance impact of Meltdown and Spectre security patches, and will be valid until March 31, 2018. This license offers unlimited users, unlimited locations and includes all standard workloads. This special license can be requested through the Login VSI website, and through selected partners in Login VSI’s extensive eco-system of (VDI-performance supporting) software, hardware and service vendors. Login VSI also started a series of lab tests to quantify the exact performance impact of the Meltdown and Spectre patches rolled out today, and will keep doing
NTT Com Granted Microsoft's Gold Cloud Platform Status Globally17.1.2018 06:00 | Pressemelding
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), is pleased to announce that it has been granted Microsoft Gold Cloud Platform status, the highest accreditation currently available, for its competency in delivering on quality, expertise and differentiated managed services in the cloud. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005911/en/ “Gold status is an important recognition of our competency in the cloud arena,” said Damian Skendrovic, CEO, NTT Com Managed Services. “With Microsoft Cloud Platform Competency we are helping enterprises to manage their hybrid cloud infrastructures, delivering on SaaS and PaaS solutions available in the Azure and Azure Stack marketplace that will enable our customers to optimize on performance and reach their business goals,” As part of its global strategy, NTT Com has been part of the early ado
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom